REVIEW

Open Access



Optimizing patient outcomes: a comprehensive evaluation of protocolized sedation in intensive care settings: a systematic review and meta-analysis

Fredy Leonardo Carreño Hernandez^{1*}, Maria Valentina Stozitzky Ríos², Yenny Rocio Cardenas Bolivar³ and Jorge Iván Alvarado Sánchez⁴

Abstract

Introduction Amidst the routine utilization of protocolized sedation in ventilated ICU patients, existing management guidelines exhibit a lack of unanimous recommendations for its widespread adoption. This study endeavors to comprehensively assess the effectiveness and safety of protocolized sedation in critically ill ventilated patients.

Objective The primary objective of this study was to systematically review and conduct a meta-analysis of clinical trials comparing protocolized sedation with standard management in critically ill ventilated patients. Key outcomes under scrutiny include ICU and hospital mortality, ventilation days, duration of ICU stay, and incidents of self-extubation. The evaluation incorporates the Risk of Bias 2 (RoB2) tool to assess the quality of included studies. Data analysis utilizes a random-effects model for relative risk (RR) and mean differences. Subgroup analysis categorizes sedation protocols into algorithmic or daily interruption, addressing potential heterogeneity. Additionally, a GRADE evaluation is performed to ascertain the overall certainty of the evidence.

Results From an initial pool of 1504 records, 10 studies met the inclusion criteria. Protocolized sedation demonstrated a reduced RR for mortality (RR: 0.80, 95% Cl 0.68–0.93, p < 0.01, $l^2 = 0\%$) and a decrease in ventilation days (mean difference: -1.12, 95% Cl -2.11 to -0.14, p = 0.03, $l^2 = 84\%$). Furthermore, there was a notable reduction in ICU stay (mean difference: -2.24, 95% Cl -3.59 to -0.89, p < 0.01, $l^2 = 81\%$). However, incidents of self-extubation did not exhibit a significant difference (RR: 1.20, 95% Cl 0.49-2.94, p = 0.69, $l^2 = 35\%$). Subgroup analyses effectively eliminated heterogeneity ($l^2 = 0\%$), and the GRADE evaluation yielded moderate results for mortality, ventilation days, and ICU duration.

Conclusion Protocolized sedation, whether implemented algorithmically or through daily interruption, emerges as a safe and effective approach when compared to standard management in ventilated ICU patients. The findings from this study contribute valuable insights to inform evidence-based practices in sedation management for this critical patient population.

Keywords Sedation, Protocolized sedation, ICU, Ventilation

*Correspondence: Fredy Leonardo Carreño Hernandez fredyleonardoc@gmail.com Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

In the realm of critical care, sedative agents play an indispensable role in addressing pain, managing agitation, ensuring proper sleep, and, most crucially, facilitating effective ventilation in patients undergoing invasive procedures. This challenge is further complicated by the intricacies brought on by the COVID-19 pandemic. Sedation in the context of invasive ventilation introduces a host of complications, ranging from difficulties with self-extubation and ventilatoracquired pneumonia (VAP) to prolonged stays in the intensive care unit (ICU) [1].

To navigate these challenges, diverse strategies have been developed, encompassing the selection of appropriate sedatives, and refining their administration methods and frequencies. One particularly promising approach is protocolized sedation, involving meticulous titration of a patient's sedation levels, which has demonstrated efficacy in reducing the duration of ventilator support [2]. Protocolized sedation can be further delineated into algorithmic protocols, daily interruptions, or a combination thereof.

However, systematic assessments of protocolized sedation in ventilated patients aimed at averting adverse events have faced hurdles. A glaring example is the 2018 Pain, Agitation/Sedation, Delirium, Immobility (Rehabilitation/Mobilization), and Sleep (Disruption) (PADIS) guideline. This guideline lacks consensus regarding the use of protocolized sedation in sedated patients to mitigate adverse events in ventilated patients [3]. This uncertainty is rooted in a systematic review with meta-analysis conducted in 2015 by Minhas, which aimed to establish whether protocolized sedation could curtail ventilation time, mortality rates, the incidence of self-extubating, or ICU length of stay [4]. However, Minhas' analysis only yielded conclusive evidence for the latter parameter. Additionally, new studies have been published, and it is necessary to obtain current evidence on this important topic.

This study aims to evaluate the impact of protocolized sedation on clinical outcomes in critically ill patients receiving mechanical ventilation in the intensive care unit (ICU). It involves comparing the effects of protocolized sedation, implemented through careful titration, with conventional sedation lacking a specific titration protocol. Primary outcome includes patient mortality and secondary outcomes include incidence of ventilator-associated pneumonia (VAP), self-extubation rates, and both duration of ICU stay and ventilation days.

Methodology

Protocol

This meta-analysis adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) recommendations [5]. The comprehensive and predefined protocol has been registered with PROSPERO[™] under the registration number CRD42023392876 (https://www.crd.york.ac.uk/prosp ero/display_record.php?RecordID=392876).

Search strategy and data extraction

A search was conducted on MEDLINE, COCHRANE, and EMBASE up to November 2022, along with clinical trial databases such as ClinicalTrials.gov and the International Clinical Trials Registry Platform (ICTRP) of the World Health Organization. The search was focused on records in Spanish and English as outlined in the PROSPERO protocol. Two authors (F, L, C; V, S) independently reviewed titles and potentially eligible abstracts using the Rayyan[®] tool. Discrepancies were resolved through consensus among the authors.

Inclusion criteria

Studies meeting the following PICOS criteria were included:

- Participants: Intensive care unit patients requiring invasive ventilation for any reason.
- Interventions encompassed protocolized sedation, wherein nurses or physicians employed a titration strategy. Protocolized sedation referred to the application of standardized approaches for managing sedation in ICU patients, such as utilizing a sedation algorithm or implementing daily sedation interruption. In contrast, usual care involved no protocolized, discretion-based sedation management, where clinicians directed the sedation process.
- Comparator: Protocolized sedation vs usual care.
- Outcomes:
 - Primary: Mortality.
 - Secondary: VAP, self-extubating, both ventilation and ICU length of days.
- Study types: Randomized clinical trials with or without blinding and concealment.

Articles meeting any of the following criteria were excluded: language other than Spanish or English, inability to access the full text, only measures of association without raw data, case reports or series, observational and quasiexperimental studies, and abstract congress.

Risk of bias assessment

Two authors (F, L, C; V, S) conducted a risk of bias assessment using the Risk of Bias 2 (RoB2) tool [6]. Discrepancies were resolved through consensus among the authors. This tool was employed to evaluate potential biases in the included clinical trials, focusing on aspects such as randomization, intervention deviation, data loss, outcome measurement errors, and selectivity in data reporting.

Data items

Data extraction was manually performed by two researchers (F, L, C; V, S) and recorded in an Excel[©] sheet. Discrepancies were resolved through consensus among the authors. Extracted variables included primary author, publication year, country, sedatives used, exclusion criteria, total patients, intervention and comparator patient counts, mortality, mean age, frequency of comorbidities, surgical and trauma frequencies, ventilation cause, self-extubating frequency, days in ICU, and days on ventilation.

Statistical analysis

A rigorous meta-analysis was performed using Review Manager 5 (RewMan5[©]) software. The analysis employed appropriate statistical methods for both dichotomous and continuous outcomes. For dichotomous outcomes such as VAP, mortality, and self-extubating, the weighted relative risk (RR) was calculated. This involves pooling data from individual studies and calculating a summary estimate of the effect size, considering both the sample size and effect size of each study. The random-effects model was applied to account for potential heterogeneity across studies. For continuous variables, such as ICU length of stay and days on ventilation, standardized mean differences was calculated. This involves comparing the mean outcomes between groups while standardizing for the scale of measurement. The random-effects model was utilized for this analysis. In cases where data are reported in medians with interguartile ranges or other nonmean formats, a conversion to means was performed using Sean McGrath's Box–Cox method [7]. This approach ensures consistency in data representation, allowing for appropriate inclusion in the meta-analysis.

Heterogeneity among studies was assessed using the Cochran Q statistic and the I^2 index. A significant Q statistic or high I^2 value may indicate substantial heterogeneity, prompting further investigation [8]. Subgroup analyses were conducted between studies that utilized daily interruption or algorithmic sedation as a form

of sedation protocols. This would help explore potential variations in outcomes related to different sedation strategies.

Additional assessment

Sensitivity analysis was performed to assess the robustness of the findings. This involves systematically varying aspects of the analysis, such as excluding studies with a high risk of bias, to evaluate the impact on the overall results. Publication bias was evaluated using funnel plots. These graphical representations will assess the symmetry of the distribution of effect sizes, aiding in the detection of potential bias toward the publication of studies with significant results.

To assess the certainty of evidence for each outcome, the GRADE approach [9] was followed. Certainty levels (high, medium, low, or very low) was assigned based on judgments about the randomization process, intervention deviation, data loss, outcome measurement, selection of reported results, and overall judgment. The results were summarized in an evidence table.

Results

A total of 2243 records were initially identified through multiple search engines. Subsequently, 1504 where left as for abstract review by eliminating 736 duplications. Only 45 of those abstracts underwent full-text assessment, with 10 ultimately being chosen for inclusion in this review, which also involved a meta-analysis. All 10 selected articles utilized the RASS scale for sedative titration and 9 out 10 studies incorporated benzodiazepines into their pharmacological regimens.

Among the reported studies, only 2 did not provide information on the reasons for patient intubation, and none reported occurrences of ventilator-associated pneumonia. Additionally, all excluded patients had experienced resuscitation from cardiorespiratory arrest, displayed neurological deficits, needed muscle blockers, were in an imminent death situation, or were anticipated to spend less than 24 h in the ICU. The screening process is visually represented in Fig. 1, detailed characteristics of the studies can be found in Table 1 and Additional file 1: Table S1.

General characteristics of the studies included

The majority of the studies were conducted in the USA, and they encompassed various types of sedative drugs. Among these studies, five specifically assessed sedation algorithms as a form of protocolized sedation. In contrast, four studies implemented daily sedation interruption, and another utilized both daily sedation




Fig. 1 PRISMA flowgram

interruption and a sedation algorithm as part of their approaches to protocolized sedation.

Risk of bias

Of the 10 included studies, none had a high risk of bias for any component, only one had some concerns of bias in the component in the randomization process, and 7 studies had some concerns of bias in the missing data by nonreporting component. In the other components, all studies presented a low risk of bias. The complete evaluation with the RoB2 tool can be found in Table 2.

Synthesis of results

In terms of mortality, a statistically significant reduction was observed with protocolized sedation compared to usual ICU management, as indicated by an RR of 0.80 [95% CI 0.68–0.93, I^2 =0%; p<0.01]. Both sedation

protocols involving daily interruption (RR=0.79, 95% CI 0.63–0.99, I^2 =0%, p=0.04) and algorithm-based sedation (RR=0.82, 95% CI 0.66–1.03, I^2 =0%, p=0.09) contributed to decreased mortality. Conversely, in the context of self-extubation events, protocolized sedation did not show a significant decrease compared to usual ICU management, with an RR of 1.20 [95% CI 0.49–2.94, I^2 =35%; p=0.69].

Regarding ventilation-related outcome, analysis of nine studies revealed that protocolized sedation led to a reduction in ventilation days by 1.12 days [95% CI – 2.11 to – 0.14, I^2 =89%; p=0.03]. Notably, daily interruption demonstrated a more pronounced effect, showing a decrease of 2.50 days [95% CI – 3.19 to – 1.81, I^2 =0%; p<0.01], while algorithm-based sedation was not statistically significant, resulting in 1.15 fewer days [95% CI – 2.48 to – 0.18, I^2 =87%; p=0.9]. Furthermore, for

Table 1 General ch	aracteristi	Table 1 General characteristic of included studies			
Author—year	Country	Country Sedatives used	<i>n</i> Intervention/ comparison	Sedation protocol methodology	Criteria exclusion
Taran—2019 [10]	Iran	Fentanyl, methadone, midazolam, haloperidol, morphine, thiopental	39 40	Algorithm	Extubating and alertness in the first 24 h, modification or, suspension of a drug prescribed by the attending physician, transfer to the operating room for surgery, Glasgow criteria below 5 and initiation of continuous infusion of sedative
Brook—1999 [11]	NSA	Propofol, haloperidol, fentanyl, lorazepam, diazepam	162 159	Algorithm	Were temporarily (<24 h) admitted to the medical intensive care unit from a surgical ward while awaiting a surgical intensive care unit bed
Weisbrodt—2011 [12] USA	USA	Fentanyl, midazolam, propofol	26 24	Daily interruption	Had a neurological or neurosurgical diagnosis at admission, drug overdose, could not understand English, as do not resusci- tated orders
Anifantaki—2009 [1 <mark>3</mark>]	Greece	Remifentanil, propofol, midazolam	49 48	Daily interruption	Pregnancy, transfer to the ICU after resuscitation after cardiac arrest or initiation of sedative infusion in another hospital
Bucknall—2008 [14]	Australia	Fentanyl, midazolam, diazepam, haloperidol, morphine, vecuronium	153 159	Algorithm	Cardiac surgery and those admitted to the ICU who had been on the study previously
Tanios—2019 [15]	USA	Fentanyl, midazolam, propofol	28–31 29	Algorithm and algo- rithm + daily interruption	Cardiac arrest, acute neurologic injury, acute alcohol withdrawal, conditions that precludes sedation, or continuous IV opioid or sedative use ≥ 24 h
Shehabi—2013 [16]	Australia	Dexmedetomidine, propofol	21 16	Algorithm	Minors, pregnancy, neurological injury, overdose, burn injury, acute liver failure, dementia, shock
Kress—2000 [17]	USA	Midazolam, propofol	68 60	Daily interruption	Pregnancy, transfer from an outside institution where sedatives had already been administered, and admission after resuscita- tion from cardiac arrest
Girard—2008 [18]	USA	Benzodiazepines, opiates, propofol	168 167	Daily interruption	Cardiopulmonary arrest, continuous mechanical ventilation for 2 weeks or more, moribund state, withdrawal from life support, profound neurological deficits, or current enrollment in another clinical trial
Mansouri—2013 [19]	Iran	Morphine, fentanyl, sufentanil, midazolam, propofol, halop- eridol	95 105	Algorithm	Had less than 24 h of ICU stay, were expected to die in less than 48 h, had received muscle relaxants, received anticonvulsant medication for seizures, had psychological illness, or had paraly- sis of the upper extremities or immobilization in a cast

Author—year	Randomization process	Deviation from the proposed intervention	Lost data	Outcome measurement	Selection of reported results	Overall judgment
Taran—2019 [10]	?	\checkmark	\checkmark	~	\checkmark	\checkmark
Brook—1999 [11]	\checkmark	\checkmark	?	\checkmark	\checkmark	\checkmark
Weisbrodt—2011 [12]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Anifantaki—2009 [13]	\checkmark	\checkmark	?	\checkmark	\checkmark	\checkmark
Bucknall—2008 [14]	\checkmark	\checkmark	?	\checkmark	\checkmark	\checkmark
Tanios (A)—2019 [15]	\checkmark	\checkmark	?	\checkmark	\checkmark	\checkmark
Tanios (B)—2019 [15]	\checkmark	\checkmark	?	\checkmark	\checkmark	\checkmark
Shehabi—2013 [16]	\checkmark	\checkmark	?	\checkmark	\checkmark	\checkmark
Kress—2000 [17]	\checkmark	\checkmark	?	\checkmark	\checkmark	\checkmark
Girard—2008 [18]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Mansouri—2013 [19]	\checkmark	\checkmark	?	\checkmark	\checkmark	\checkmark

Table 2 Risk of bias 2 evaluation

 \checkmark = low risk; ? = some concerns




Fig. 2 Mortality forest plot by protocolized sedation methodology

the duration of ICU stay, protocolized sedation, both by sub daily interruption and algorithm, exhibited a reduction of 2.24 days [95% CI -3.59 to -0.89, $l^2 = 81\%$; p < 0.01], with

subgroup analysis reducing heterogeneity to $I^2 = 0\%$. The results are visually represented in Figs. 2, 3, 4, and 5.

	Protocolize se		Usual (Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.3.1 Algorithm							
Bucknall - 2008	2	153	1	158	10.6%	2.07 [0.19, 22.54]	
Mansouri - 2013	4	96	2	105	17.3%	2.19 [0.41, 11.67]	
Tanios (A) - 2019	0	28	1	27	6.8%	0.32 [0.01, 7.57]	
Taran - 2019	1	39	4	40	12.5%	0.26 [0.03, 2.19]	
Subtotal (95% CI)		316		330	47.2%	0.98 [0.31, 3.05]	
Total events	7		8				
Heterogeneity: Tau ² :	= 0.11; Chi ² = 3.2	5, df = 3 (P = 0.35);	l² = 8%	5		
Test for overall effect	: Z = 0.04 (P = 0.9	17)					
1.3.2 Daily interrupti	on						
Girard - 2008	16	168	4	167	26.7%	3.98 [1.36, 11.64]	
Kress - 2000	2	68	4	60	17.4%	0.44 [0.08, 2.32]	
Weisbrodt - 2011	0	26	0	24		Not estimable	
Subtotal (95% Cl)		262		251	44.2%	1.46 [0.17, 12.48]	
Total events	18		8				
Heterogeneity: Tau ² :	= 1.91; Chi ² = 4.79	5, df = 1 (P = 0.03)	l² = 79	%		
Test for overall effect	: Z = 0.34 (P = 0.7	3)					
1.3.3 Algorithm + Da	ily interruption						
Tanios (B) - 2019	1	31	1	27	8.7%	0.87 [0.06, 13.27]	
Subtotal (95% CI)		31		27	8.7%	0.87 [0.06, 13.27]	
Total events	1		1				
Heterogeneity: Not a	pplicable						
Test for overall effect	: Z = 0.10 (P = 0.9	12)					
Total (95% CI)		609		608	100.0%	1.20 [0.49, 2.94]	
Total events	26		17				
Heterogeneity: Tau ² :	= 0.48; Chi ² = 9.13	B,df=6 (P = 0.16);	l² = 35	%		
Test for overall effect		• •					0.01 0.1 i 10 10
Test for subgroup dif	•	,	2(P = 0.9)	34), I ² =	0%		protocol usual care
a. 3 Self-extubation		-					

Fig. 3 Self-extubation forest plot by protocolized sedation methodology

	Protoco	olize seda	ation	Us	ual Care	9		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.1.1 Daily interruption	on								
Anifantaki - 2009	12.23	13.16	49	11.98	11.33	48	3.2%	0.25 [-4.63, 5.13]	
Girard - 2008	7.1	7	168	9.2	8.4	167	10.5%	-2.10 [-3.76, -0.44]	
Kress - 2000	5.04	1.4	68	7.75	2.77	60	13.6%	-2.71 [-3.49, -1.93]	
Weisbrodt - 2011	10.25	8.71	26	10.72	9.1	24	3.1%	-0.47 [-5.42, 4.48]	
Subtotal (95% CI)			311			299	30.5%	-2.50 [-3.19, -1.81]	◆
Heterogeneity: Tau ² =	= 0.00; Chi ^a	²= 2.37, c	if = 3 (P	= 0.50)	l ² = 0%				
Test for overall effect:	Z=7.12 (P < 0.000	01)						
1.1.2 Algorithm									
Brook - 1999	3.7	5.5	162	5.1	5.9	159	12.0%	-1.40 [-2.65, -0.15]	
Bucknall - 2008	4.58	4.44	153	5.06	8.33	159	11.2%	-0.48 [-1.95, 0.99]	
Mansouri - 2013	0.89	0.38	96	2.11	1.75	105	14.6%	-1.22 [-1.56, -0.88]	-
Tanios (A) - 2019	5	2.71	28	3.8	0.98	27	12.7%	1.20 [0.13, 2.27]	
Taran - 2019	5	2	39	10.05	7	40	8.4%	-5.05 [-7.31, -2.79]	
Subtotal (95% Cl)			478			490	58.9%	-1.15 [-2.48, 0.18]	•
Heterogeneity: Tau ² =	= 1.85; Chi ^a	² = 30.85,	df = 4 (P < 0.00	1001); I ²	= 87%			
Test for overall effect:	Z=1.70 (F	P = 0.09)							
1.1.3 Algorithm + Dai	ily interrup	tion							
Tanios (B) - 2019	5.15	4.47	31	3.8	0.98	27	10.6%	1.35 [-0.27, 2.97]	+
Subtotal (95% CI)			31			27	10.6%	1.35 [-0.27, 2.97]	◆
Heterogeneity: Not ap	oplicable								
Test for overall effect:	Z=1.64 (F	P = 0.10)							
Total (95% CI)			820			816	100.0%	-1.12 [-2.11, -0.14]	•
Heterogeneity: Tau ² =	1.71: Chi	² = 57.15.	df = 9 (P < 0.00	1001); I ²	= 84%			
Test for overall effect:					//	/ *			-10 -5 0 5 10
Test for subgroup dif	,	,		2 (P ≪ 1	0001	I ² = 80	7%		Favours proto sedation Favours Usual care

Fig. 4 Days in ventilation forest plot by protocolized sedation methodology

	Protoco	olize seda	ation	Us	ual Care	9		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.2.1 Algorithm									
Brook - 1999	5.7	5.9	162	7.5	6.5	159	14.3%	-1.80 [-3.16, -0.44]	
Bucknall - 2008	6.3	7.66	153	5.14	5.05	159	14.1%	1.16 [-0.29, 2.61]	+
Mansouri - 2013	4.19	1.1	96	7.51	2.57	105	16.3%	-3.32 [-3.86, -2.78]	+
Shehab - 2013	6.61	2.1	21	8.23	7.41	16	7.3%	-1.62 [-5.36, 2.12]	
Tanios (A) - 2019	12.66	18.41	28	12.06	16.62	27	1.9%	0.60 [-8.66, 9.86]	
Taran - 2019	10	4	39	19	12	40	6.9%	-9.00 [-12.92, -5.08]	
Subtotal (95% CI)			499			506	60.8%	-2.37 [-4.59, -0.14]	◆
Heterogeneity: Tau ² =	5.39; Chi	² = 44.87	df = 5 (l	P < 0.00	1001); l ²	= 89%			
Test for overall effect:	Z= 2.08 (P = 0.04)							
1.2.2 Daily interruptio	n								
Anifantaki - 2009	18.46	13.54	49	15.33	10.03	48	5.5%	3.13 [-1.61, 7.87]	
Girard - 2008	9.1	9.41	168	12	10.17	167	11.9%	-2.90 [-5.00, -0.80]	
Kress - 2000	6.64	1.66	68	10.16	2.95	60	15.7%	-3.52 [-4.36, -2.68]	-
Weisbrodt - 2011	13.39	12.93	26	15.21	13.32	24	2.8%	-1.82 [-9.11, 5.47]	
Subtotal (95% CI)			311			299	35.9%	-2.24 [-4.37, -0.12]	◆
Heterogeneity: Tau ² =	2.41; Chi	² = 7.62, 0	df = 3 (P	= 0.05);	I ² = 61 9	%			
Test for overall effect:	Z= 2.07 (P = 0.04)							
1.2.3 Algorithm + Dail	ly interrup	otion							
Tanios (B) - 2019	9.23	7.02	31	12.06	16.62	27	3.2%	-2.83 [-9.57, 3.91]	
Subtotal (95% CI)			31			27	3.2%	-2.83 [-9.57, 3.91]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	•	P = 0.41)							
Total (95% Cl)			841			832	100.0%	-2.24 [-3.59, -0.89]	•
Heterogeneity: Tau ² =	2.81: Chi	² = 53.79	df = 10	(P < 0.0	0001): 1	² = 819	6		
Test for overall effect:							-		-10 -5 0 5 10
Test for subgroup diff				(P = 0)	99) I ² =	0%			protocol usual care
reactor subgroup un	0.0110005.0	- 0.0	0, ui – 2	0		0.0			

Fig. 5 Days in ICU forest plot by protocolized sedation methodology

Risk of bias across studies

No publication bias was identified, as evidenced by the absence of asymmetry in funnel plots for all evaluated outcomes, as illustrated in Fig. 6A–D. This indicates that the findings presented in this review are unlikely to be distorted by selective reporting, enhancing the robustness and reliability of the reported results.

Additional assessment

Sensitivity analysis

Given the considerable prevalence of bias related to lost data, a sensitivity analysis was conducted with a subset of 3 studies. The results for self-extubating events (RR = 1.19, 95% CI 0.08–17.22) and reduced days of ventilation (RR = 2.95, 95% CI – 5.39 to – 0.51) and ICU stay (RR = 4.82, 95% CI – 9.36 to – 0.28) maintained a consistent direction of effect, although with variations in magnitude compared to the overall results. Mortality, however, exhibited a nonsignificant RR of 0.70 (95% CI 0.48–1.02). A secondary sensitivity analysis, excluding the only study with concerns regarding the randomization process, indicated a shift in the ventilation day differences (RR = -0.78, 95% CI – 1.74 to 0.18), with no statistically significant variations identified.

GRADE assessment

Based on the comprehensive assessment of the identified risks, predominantly low in various components with some concerns related to missing data, coupled with remarkable consistency in the results and the potential explanation of heterogeneity by the type of protocolized sedation, moderate evidence was established for the effectiveness of protocolized sedation in reducing mortality, ventilation days, and ICU stay. In contrast, due to significant inconsistency in the outcomes and the inability to elucidate heterogeneity through subgroup analysis, protocolized sedation was determined to have very low evidence concerning the occurrence of self-extubating events. A detailed summary of these findings is presented in Table 3.

Discussion

In this comprehensive systematic review with metaanalysis, we scrutinized ten studies that compared the efficacy of protocolized sedation against standard care in ventilated ICU patients. Our analysis revealed substantial advantages associated with protocolized sedation, leading to a notable reduction in ventilation and ICU days and a concurrent improvement in safety indicated by lower mortality rates. Despite potential biases related to data loss, the GRADE evaluation moderately




Fig. 6 Funnel plot. A Ventilation days. B Days on ICU. C Self-extubation. D Mortality

recommends the adoption of protocolized sedation over usual care for these three critical outcomes.

Furthermore, our subgroup analyses, distinguishing between daily interruption and algorithmic continuation of protocolized sedation, consistently demonstrated benefits over usual care. However, the analysis of the reduction in self-extubating rates remains inconclusive due to insufficient data for comprehensive evaluation. Notably, the challenge of assessing the specific intervention combining both daily interruption and algorithmic protocols arises from the limited number of studies with this unique cohort.

Association with previous studies

Our systematic review and meta-analysis significantly build upon the foundation laid by Minhas et al. in 2015 [4]. By identifying two new studies and incorporating two previously overlooked studies, our findings reveal a decrease in mortality associated with protocolized sedation, contrasting with Minhas' earlier report. This discrepancy underscores the importance of our review's inclusivity, enabling the detection of nuanced differences between the intervention and the comparator. Similar trends were observed in the reduction in ICU length of stay and ventilation days, reinforcing the efficacy of protocolized sedation.

An intriguing aspect of our analysis involved subgroup assessments based on the type of protocolized sedation employed. The distinctions between algorithmic and daily interruption protocols, while both adhering to specific guidelines, became evident in the respective outcomes, showcasing variations in relative risk (RR) and mean differences for each type of protocolized sedation.

It is noteworthy that, despite the absence of blinding in the intervention across all studies, the impact on outcomes was minimal. This can be attributed to the study's

No. of	Study	Risk of bias	Risk of bias Certainty assessment	sment	Vagueness Other	Other	No. of patients	s	Effect		Certainty	Importance
studies	design		Inconsistency	Indirect evidence		considerations	Protocolized Usual care sedation	Usual care	Relative (95% Cl)	Absolute (95% Cl)		
Mortality 10	Randomized Serious trials	Serious	Not serious	Not serious	Not serious None	None	260/1037 (25.1%)	335/1058 (31.7%)	OR 0.80 (0.70 to 0.92)	46 less per 1000 (from 72 to 18 less)	00000000000000000000000000000000000000	CRITICAL
Ventilation days 8 t	lays Randomized trials	Serious	Not serious	Not serious	Not serious None	None	820	816	I	MD 1.12 days $\oplus \oplus \oplus$	00000000000000000000000000000000000000	IMPORTANT
Length of days in ICU 10 Randu trials	omized	Serious	Not serious	Not serious	Not serious None	None	1038	1058	I	2.3 days 3.58 0 1.02	000 Moderate	IMPORTANT
Self-extubation 7	Randomized trials	Serious	Very serious	Not serious	Very serious None	None	26/609 (4.3%)	26/609 (4.3%) 17/608 (2.8%) OR 1.20 (0.49 to 2.94)	OR 1.20 (0.49 to 2.94)	5 more for 1000 (from 14 less to 50 more)	ery low	IMPORTANT
<i>Cl</i> confidence	Cl confidence interval, MD mean difference, OR odds ratio	difference, <i>OR</i> od	lds ratio									

Table 3 GRADE assessment

focus on objective and concrete outcomes, resulting in a low risk of bias.

Significance and implications

The implications of our systematic review on the management of ventilated patients are profound, particularly considering the previous absence of a recommendation for protocolized sedation in the PADIS 2018 guidelines due to insufficient evidence. With the presented findings and the anticipated release of the updated PADIS 2023 guide, we anticipate influencing forthcoming recommendations. Moreover, we advocate for the PADIS 2023 guide to differentiate between algorithmic protocolized sedation and daily interruption, facilitating more precise and tailored recommendations.

The consistency in exclusion criteria across the studies allows us to identify specific patient populations for whom this intervention might be less effective. Understanding the reasons behind patient intubation further enables the identification of those who could benefit most from protocolized sedation.

Looking forward, conducting clinical trials directly comparing different types of protocolized sedation, including combined approaches, becomes imperative. Our systematic review predominantly compared protocolized sedation against continuous infusion or daily sedation management, preventing a conclusive determination of the superiority of one protocolized sedation method over another due to the lack of direct comparative studies.

Conclusions

In conclusion, protocolized sedation demonstrates a significant reduction in mortality, ventilation days, and ICU stay compared to standard sedation management for intubated ICU patients. However, distinctions between algorithmic protocolized sedation and diurnal interruption exist, emphasizing the need for specific clinical trials directly comparing these methods. The insights provided by our study contribute to advancing evidence-based practices in sedation management for ventilated ICU patients.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40001-024-01839-y.

Additional file 1: Table S1. General characteristic of included studies.

Acknowledgements

We do not have acknowledgments.

Author contributions

Design: FLCH, YRCB, VS: performed the literature review: FLCH, VS: acquisition of data: FC, VS: interpretation of data: all authors. Wrote the manuscript: all authors.

Funding

The author(s) received no financial support for the research, authorship, and/ or publication of this article.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate Does not apply.

Consent for publication

Does not apply.

Competing interests

The author(s) declare that they do not have competing interests.

Author details

¹Clinical Research, Universidad de los Andes, School of medicine, Bogotá, Colombia. ²Clinical Research, Fundación Santa Fe de Bogotá, Bogotá, Colombia. ³Intensive Care Unit, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia. ⁴Intensive Care Unit, Hospital Universitario Fundación Santa Fe de Bogotá, Universidad Nacional de Colombia, Bogotá, Colombia.

Received: 4 December 2023 Accepted: 10 April 2024 Published online: 24 April 2024

References

- Page V, McKenzie C. Sedation in the intensive care unit. Curr Anesthesiol Rep. 2021;11:92–100. https://doi.org/10.1007/s40140-021-00446-5.
- Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomized trial. Lancet. 2010;375(9713):475–80.
- Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):E825–73.
- Minhas MA, Velasquez AG, Kaul A, Salinas PD, Celi LA. Effect of protocolized sedation on clinical outcomes in mechanically ventilated intensive care unit patients: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(5):613–23.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https://doi.org/10.1136/bmj.n71.
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366: I4898.
- McGrath S, Zhao XF, Steele R, Thombs BD, Benedetti A, Levis B, et al. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020;29(9):2520–37. https://doi.org/10.1177/0962280219889080?journ alCode=smma.
- Deeks JJ, Higgins JPT, editors. 9.5.2 Identifying and measuring heterogeneity. Chapter 9 Sect Anal data Undert meta-analyses 952 Higgins JPT, Green S (editors) Cochrane Interv Handb Syst Rev Cochrane, version 502 (updated Sept 2009) Collab 2009. 2009;(i):100. https://handbook-5-1. cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heter ogeneity.htm. Accessed 31 Aug 2022.
- Higgins J, Green S. 12.2.1 The GRADE approach. In: Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. https://handb

ook-5-1.cochrane.org/chapter_12/12_2_1_the_grade_approach.htm. Accessed 31 Aug 2022.

- Taran Z, Namadian M, Faghihzadeh S, Naghibi T. The effect of sedation protocol using richmond agitation sedation scale (RASS) on some clinical outcomes of mechanically ventilated patients in intensive care units: a randomized clinical trial. J Caring Sci. 2019;8(4):199–206.
- Brook AD, Ahrens TS, Schaiff R, Prentice D, Sherman G, Shannon W, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med. 1999;27(12):2609–15.
- Mehta S, Burry L, Cook D, Fergusson D, Steinberg M, Granton J, et al. Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial. JAMA. 2012;308(19):1985–92.
- Anifantaki S, Prinianakis G, Vitsaksaki E, Katsouli V, Mari S, Symianakis A, et al. Daily interruption of sedative infusions in an adult medicalsurgical intensive care unit: randomized controlled trial. J Adv Nurs. 2009;65(5):1054–60.
- Bucknall TK, Manias E, Presneill JJ. A randomized trial of protocol-directed sedation management for mechanical ventilation in an Australian intensive care unit. Crit Care Med. 2008;36(5):1444–50.
- Tanios M, Nguyen HM, Park H, Mehta S, Epstein SK, Youssef F, et al. Analgesia-first sedation in critically ill adults: a US pilot, randomized controlled trial. J Crit Care. 2019;53:107–13.
- Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, et al. Early goaldirected sedation versus standard sedation in mechanically ventilated critically III patients: a pilot study. Crit Care Med. 2013;41(8):1983–91.
- Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342(20):1471–7. https://doi.org/10.1056/nejm200005 183422002.
- Girard TD, Kress JP, Fuchs BD, Thomason JWW, Schweickert WD, Pun BT, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (awakening and breathing controlled trial): a randomized controlled trial. Lancet. 2008;371(9607):126–34.
- Mansouri P, Javadpour S, Zand F, Ghodsbin F, Sabetian G, Masjedi M, et al. Implementation of a protocol for integrated management of pain, agitation, and delirium can improve clinical outcomes in the intensive care unit: a randomized clinical trial. J Crit Care. 2013;28(6):918–22.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.